DEAL ANNOUNCEMENT / PRESS RELEASE
February 26, 2025
Read time: 3 min
International law firm McDermott Will & Emery represented VION Biosciences, portfolio company of Iron Path Capital and life science platform focused on specialty materials in the life science research, diagnostics and drug discovery spaces, in its acquisition of BioAssay Systems, a San Francisco-based biotech company that develops and offers innovative high-throughput assay solutions for life sciences and drug discovery. This transaction will provide a reliable, high-quality solution for companies and organizations performing critical research in the life science space.
David Ivill and Krist Werling are the relationship partners for Iron Path Capital. The McDermott team was led by Hunter Sharp and Terry Brennan with invaluable support from provided from Elizabeth Amanieh, Alejandro Ruiz, John Zhang, Jamie Ravitz, Paul Gadiock, Karis Jackson, Marissa Hill Daley, David Levine, Jennifer Levengood, Brian Mead, Brian Casillas, Jeff Holdvogt, Scott Kenkel, David Saunders, Jennifer Mikulina, Ashley Brezinski, Jacob Hollinger, Kristi Mankowske, Elena Otero and Betty Brito.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
